



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

May 19, 2023

Kenneth Myszkowski  
Chief Financial Officer  
Arrowhead Pharmaceuticals, Inc.  
177 E. Colorado Blvd, Suite 700  
Pasadena, California 91105

**Re: Arrowhead Pharmaceuticals, Inc.**  
**Form 10-K for the Fiscal Year Ended September 30, 2022**  
**Filed November 28, 2022**  
**File No. 001-38042**

Dear Kenneth Myszkowski:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences